Q4 EPS Estimate for Catalyst Pharmaceuticals Cut by Analyst

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) – Equities research analysts at Zacks Research lowered their Q4 2024 earnings per share estimates for shares of Catalyst Pharmaceuticals in a report released on Wednesday, November 27th. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will earn $0.46 per share for the quarter, down from their previous estimate of $0.48. The consensus estimate for Catalyst Pharmaceuticals’ current full-year earnings is $1.90 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals’ Q3 2025 earnings at $0.54 EPS, Q4 2025 earnings at $0.57 EPS, Q2 2026 earnings at $0.58 EPS and FY2026 earnings at $2.36 EPS.

A number of other research analysts have also issued reports on the company. Truist Financial increased their target price on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, November 11th. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 9th. Stephens began coverage on Catalyst Pharmaceuticals in a research report on Monday, November 18th. They set an “overweight” rating and a $35.00 target price on the stock. HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, November 8th. Finally, Citigroup increased their target price on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Catalyst Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $31.14.

Catalyst Pharmaceuticals Trading Down 3.6 %

Catalyst Pharmaceuticals stock opened at $21.71 on Monday. Catalyst Pharmaceuticals has a 12 month low of $13.00 and a 12 month high of $24.27. The stock’s 50 day simple moving average is $21.32 and its two-hundred day simple moving average is $18.87. The firm has a market cap of $2.59 billion, a PE ratio of 18.40, a P/E/G ratio of 3.44 and a beta of 0.75.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. Franklin Resources Inc. grew its holdings in shares of Catalyst Pharmaceuticals by 3.4% during the 3rd quarter. Franklin Resources Inc. now owns 59,164 shares of the biopharmaceutical company’s stock worth $1,221,000 after purchasing an additional 1,967 shares during the period. Sanctuary Advisors LLC purchased a new position in shares of Catalyst Pharmaceuticals during the 3rd quarter worth $667,000. Hohimer Wealth Management LLC purchased a new position in shares of Catalyst Pharmaceuticals during the 3rd quarter worth $329,000. Vestcor Inc boosted its holdings in Catalyst Pharmaceuticals by 18.4% during the 3rd quarter. Vestcor Inc now owns 60,431 shares of the biopharmaceutical company’s stock valued at $1,201,000 after acquiring an additional 9,379 shares during the period. Finally, Barclays PLC boosted its holdings in Catalyst Pharmaceuticals by 129.4% during the 3rd quarter. Barclays PLC now owns 248,458 shares of the biopharmaceutical company’s stock valued at $4,939,000 after acquiring an additional 140,129 shares during the period. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, Director Molly Harper sold 17,500 shares of the firm’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total value of $385,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Gary Ingenito sold 12,000 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total value of $272,640.00. Following the transaction, the insider now owns 51,391 shares of the company’s stock, valued at approximately $1,167,603.52. This represents a 18.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 11.00% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.